Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled ...
Myeloma risk prediction is strong, but matching each patient to optimal therapy is still being tested, says Nikhil C. Munshi, ...
Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why oral options like iberdomide and clinical trials matter in the immunotherapy era of myeloma.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates ...
ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when disease relapsed as AML after transplant.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and ...
Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental ...
A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven ...
SMART-MASH found about a third more patients with cirrhosis than Agile 4 while using costly fibrosis tests in only some ...
Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at ...
Started at advanced fibrosis or cirrhosis, pegozafermin lowered liver collagen below baseline and prevented liver cancer in a ...
The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results